LBIO (Longevity Biomedical) LT-Debt-to-Total-Asset: 0.00 (As of . 20)


What is Longevity Biomedical LT-Debt-to-Total-Asset?

Longevity Biomedical LBIO LT-Debt-to-Total-Asset is 0.00 as of . 20.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Longevity Biomedical's long-term debt to total assests ratio for the quarter that ended in . 20 was 0.00.

Longevity Biomedical's long-term debt to total assets ratio stayed the same from . 20 (0.00) to . 20 (0.00).

Longevity Biomedical  (NAS:LBIO) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Longevity Biomedical LT-Debt-to-Total-Asset Related Terms

Longevity Biomedical LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Longevity Biomedical's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Longevity Biomedical LT-Debt-to-Total-Asset Chart

Longevity Biomedical Annual Data
Trend
LT-Debt-to-Total-Asset

Longevity Biomedical Semi-Annual Data
LT-Debt-to-Total-Asset

Longevity Biomedical LT-Debt-to-Total-Asset Calculation

Longevity Biomedical's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in . 20 is calculated as

LT Debt to Total Assets (A: . 20 )=Long-Term Debt & Capital Lease Obligation (A: . 20 )/Total Assets (A: . 20 )
=/
=

Longevity Biomedical's Long-Term Debt to Total Asset Ratio for the quarter that ended in . 20 is calculated as

LT Debt to Total Assets (Q: . 20 )=Long-Term Debt & Capital Lease Obligation (Q: . 20 )/Total Assets (Q: . 20 )
=/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Longevity Biomedical (LBIO) has a LT-Debt-to-Total-Asset of 0.00 as of . 20. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Longevity Biomedical and its competitors.
Is Longevity Biomedical's LT-Debt-to-Total-Asset too high?
Longevity Biomedical's current LT-Debt-to-Total-Asset is 0.00.
How does Longevity Biomedical's LT-Debt-to-Total-Asset compare to ?
Longevity Biomedical's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Longevity Biomedical and its competitors. Longevity Biomedical's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longevity Biomedical stock overvalued right now?
Longevity Biomedical (LBIO) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Longevity Biomedical (LBIO), the current LT-Debt-to-Total-Asset is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Longevity Biomedical Business Description

Comparable Companies
Address 12100 NE 195th street, Suite 150, Bothell, WA, USA, 98011
Longevity Biomedical Inc is a clinical-stage biomedical company. The company is focused on the advancement of new technologies across therapeutics, monitoring, and digital health that aim to restore tissue form and function to increase health span. Longevity is acquiring a differentiated therapeutic pipeline of late-stage clinical technologies across ophthalmology, cardiovascular disease, and soft tissue reconstruction and repair.